Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis
- Category: Small Molecules
- Published on Tuesday, 22 March 2022 13:12
- Hits: 1984
Ribon’s portfolio now includes two first-in-class clinical programs, RBN-2397 and RBN-3143, targeting broad indications in oncology and inflammatory diseases
CAMBRIDGE, MA, USA I March 22, 2022 I Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it initiated the healthy volunteer portion of its Phase 1, first-in-human, single ascending dose and multiple ascending dose (SAD/MAD) safety and pharmacokinetic study of RBN-3143. RBN-3143 is a novel, orally administered, first-in-class inhibitor of PARP14 with potential as a therapy in a range of inflammatory diseases, with an initial focus in atopic dermatitis. PARP14 is highly expressed in tissues of inflammatory diseases, aiding the infiltration of inflammatory cells such as eosinophils and neutrophils, the reduction of which has potential advantages over current therapies.
“Today’s news of the initiation of RBN-3143, our second program to move into the clinic, is an important advancement for Ribon that broadens our Company’s portfolio to now include first-in-class programs in both oncology and inflammatory diseases, leveraging our pioneering research in the role of NAD+-utilizing enzymes in stress support pathways,” said Prakash Raman, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. “As a first-in-class, oral small molecule inhibitor of PARP14, RBN-3143 has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases. We look forward to progressing this important study.”
“Based upon our extensive research and expertise evaluating NAD+-utilizing enzymes in stress support pathways, we identified that PARP14 expression is elevated in multiple tissues undergoing chronic inflammation, including atopic dermatitis, psoriasis, and asthma,” said Heike Keilhack, Ph.D., Chief Scientific Officer, Ribon Therapeutics. “By inhibiting PARP14, RBN-3143 has the potential to broadly treat inflammatory diseases with an oral agent. In preclinical inflammatory disease models, we observed that oral dosing with RBN-3143 led to a decrease of key inflammatory cytokines and cells such as eosinophils and neutrophils as well as significant improvement of disease symptoms. Further, RBN-3143 was safe and well-tolerated in preclinical studies. We look forward to further investigating the clinical profile of RBN-3143 to understand its potential to help patients with unmet needs.”
PARP14 is a NAD+-utilizing monoART (mono-ADP-ribosyltransferase) controlling cell signaling and regulating protein function. PARP14 expression is elevated in tissues of various inflammatory diseases, but it is not highly expressed in normal tissues. High PARP14 expression leads to the increase of first order cytokines, specifically alarmins, and second order cytokines, Th2 and Th17 cytokines, and ultimately the increase in disease tissue eosinophils and neutrophils which drive pathology.
RBN-3143, a first-in-class, oral small molecule inhibitor of PARP14, has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases. This is the second program emerging from the BEACON+ platform to enter clinical development. Selective inhibition of PARP14 leads to a decrease in alarmins and dampening of the IL-17 and IL-4/13 signaling pathways. Ribon has demonstrated efficacy in multiple preclinical models of inflammatory disease. RBN-3143 is currently being evaluated in a Phase 1 clinical study in healthy volunteers and atopic dermatitis patients.
About Ribon Therapeutics
Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. The company explores novel areas of biology to develop effective treatments for patients with limited therapeutic options and has active clinical programs in oncology and inflammatory disease. Leveraging our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoARTs (mono-ADP-ribosyltransferase), which have applications across multiple therapeutic areas. Ribon is located in Cambridge, Massachusetts. For more information, visit https://ribontx.com/.
SOURCE: Ribon Therapeutics